Steroid-Sparing Effect Of Mepolizumab In Children With Severe Eosinophilic Nonallergic Asthma

Abstract

Background: Asthma is characterized by a chronic airway inflammation, usually sustained by type 2 immunity. Bronchial and peripheral eosinophilia are biomarkers for type 2 asthma. Biologicals are the most effective treatment for severe asthma at present. Mepolizumab is an antagonist of interleukin-5 (IL-5), the most relevant cytokine involved in eosinophilia. Objective This case report evaluated the effectiveness of mepolizumab in two girls with severe eosinophilic non-allergic asthma. Materials and methods Two female children with severe eosinophilic nonallergic asthma were asthma control, and bronchial endoscopy were performed. Results Biologicals reduced the eosinophilia, asthma exacerbations, and improved lung function in both patients. The treatment was also safe and well-tolerated. Conclusion: Mepolizumab represents an effective therapeutic option in the management of severe pediatric asthma.